

Attorney Docket No.: 5218-39B

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Anagnostou et al.

Group Art Unit: 1642

Application Serial No.: 09/525,797

Examiner: Susan Unger

Filed: March 15, 2000

Confirmation No.: 9917

For: METHOD OF TREATING ENDOTHELIAL INJURY

Date: November 29, 2006

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(d)**

Dear Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each identified document. Also enclosed is a translation or a concise explanation of each non-English language document. This Information Disclosure Statement is being filed in accordance with the requirements of 37 C.F.R. 1.97(d).


In accordance with the requirements of 37 C.F.R. § 1.97(d)(1), the following certification as specified in 37 C.F.R. § 1.97(e)(1) is made:

Each item of information contained in this Information Disclosure Statement was first cited in a communication presented to a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement, and more specifically, during an Opposition Proceeding in corresponding European Patent No. 0933995 (European Patent Application No. 97940974.5).

In accordance with the requirements of 37 C.F.R. § 1.97(d)(2), the Commissioner is authorized to charge \$180.00 to Deposit Account No. 50-0220 for the fee specified in 37 C.F.R. § 1.17(p). This amount is believed to be correct; however, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.


Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428, Raleigh, NC 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

Respectfully Submitted,


Shawna Cannon Lemon
Registration No. 53,888

**CERTIFICATION OF ELECTRONIC TRANSMISSION
UNDER 37 CFR § 1.8**

I hereby certify that this correspondence is being transmitted electronically to the U.S. Patent and Trademark Office on November 29, 2006.


Evelyn B. Casey; Date of Signature: November 29, 2006

Substitute form 1449A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/525,797
		Filing Date	March 15, 2000
		First Named Inventor	Anagnostou et al.
		Group Art Unit	1642
		Examiner Name	Susan Ungar
Sheet	1 of 1	Attorney Docket Number	5218-39B

U.S. PATENT APPLICATIONS				
Examiner Initials*	Cite No.	U.S. Serial No.	Name of Applicant of Cited Document	Date of Filing of Cited Document MM-DD-YYYY
		US-		

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1.	Breymann et al. "Optimal timing of repeated rh-erythropoietin administration improves its effectiveness in stimulating erythropoiesis in healthy volunteers" <i>Br J Haematol.</i> 92 (2):295-301 (1996)	
	2.	Ito et al. "Vitamin E prevents endothelial injury associated with cisplatin injection into the superior mesenteric artery of rats" <i>Heart Vessels</i> 10 (4):178-84 (1995)	
	3.	Komatsu et al. "Multiple cerebral infarction after treatment with cisplatin" <i>Rinsho Shinkeigaku</i> 36 (3):499-502 (1996)	abstract

Examiner Signature _____ Date Considered _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.